Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 18, 2017 - Issue 15
Submit an article Journal homepage
295
Views
7
CrossRef citations to date
0
Altmetric
Meta-Opinion

Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion

Emanuele D’AmicoMS center, ULSS 6 Padova, ItalyCorrespondence[email protected]
View further author information
,
Tjalf ZiemssenCenter of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, GermanyORCID Iconhttp://orcid.org/0000-0001-8799-8202View further author information
ORCID Icon &
Salvatore CottoneMS Center Dept. Neurology A.O.O.R. Villa Sofia-Cervello, Palermo, ItalyView further author information
Pages 1553-1556 | Received 30 Apr 2017, Accepted 08 Aug 2017, Published online: 22 Aug 2017

References

  • Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15;83(3):278–286.
  • Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263(6):1053–1065.
  • Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: Why? When? How? CNS Drugs. 2013 Jun;27(6):403–409.
  • Fernández O, Delvecchio M, Edan G, et al. Survey of diagnostic and treatment practices for multiple sclerosis in Europe. Eur J Neurol. 2017 Mar;24(3):516–522. Epub 2017 Jan 31. DOI:10.1111/ene.13236
  • Ziemssen T, Kern R, Thomas K. Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurol. 2016;16:124.
  • Kaunzner UW, Kumar G, Askin G, et al. A study of patients with aggressive multiple sclerosis at disease onset. Neuropsychiatr Dis Treat. 2016 Aug;1(12):1907–1912.
  • Rottlaender A, Kuerten S. Stepchild or prodigy? Neuroprotection in multiple sclerosis (MS) research. Int J Mol Sci. 2015 Jul 1;16(7):14850–14865.
  • Comi G, Radaelli M, Soelberg Sørensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017 Apr 1; 389(10076):1347–1356.
  • Villaverde-González R, Gracia Gil J, Pérez Sempere A, et al. Observational study of switching from natalizumab to immunomodulatory drugs. Eur Neurol. 2017;77(3–4):130–136.
  • Beran RG, Hegazi Y, Schwartz RS, et al. Rebound exacerbation multiple sclerosis following cessation of oral treatment. Mult Scler Relat Disord. 2013 Jul;2(3):252–255.
  • Van Obberghen EK, Cohen M, Rocher F, et al. Multiple immune disorders after natalizumab discontinuation: after the CIRIS, the SIRIS? Rev Neurol (Paris). 2017 Mar 31;173:222–224.
  • Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015 Jan;8(1):31–45.
  • Hassoun L, Eisele J, Thomas K, et al. Hands on alemtuzumab-experience from clinical practice: whom and how to treat. Mult Scler Demyelinating Disord. 2016;1(1):10.
  • Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol Sci. 2008 Sep;29(Suppl 2):S253–5.
  • Edan G, Comi G, Le Page E, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1344–1350.
  • Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):52–56.
  • Le Page E, Leray E, Edan G. French Mitoxantrone Safety Group. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler. 2011 Jul;17(7):867–7516.
  • D’Amico E, Zanghì A, Patti F. Personalized therapy in multiple sclerosis: state of art and future perspectives. Expert Rev Precision Med Drug Dev. 2016;1(4):353–360.
  • McLauchlan D, Robertson NP. B cell treatments for multiple sclerosis. J Neurol. 2017 Apr;264(4):814–816.
  • Comi G, Hartung HP, Kurukulasuriya NC, et al. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother. 2013 Jan;14(1):123–136.
  • Costelloe L, Thompson A, Walsh C, et al. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry. 2008;79(11):1245–1248.
  • Giovannoni G, Tomic D, Bright JR, et al. “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23(9):1179–1187.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.